JP2014532886A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014532886A5 JP2014532886A5 JP2014540427A JP2014540427A JP2014532886A5 JP 2014532886 A5 JP2014532886 A5 JP 2014532886A5 JP 2014540427 A JP2014540427 A JP 2014540427A JP 2014540427 A JP2014540427 A JP 2014540427A JP 2014532886 A5 JP2014532886 A5 JP 2014532886A5
- Authority
- JP
- Japan
- Prior art keywords
- lipid
- compared
- control
- sample
- cvd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037998 chronic venous disease Diseases 0.000 claims description 142
- 150000002632 lipids Chemical class 0.000 claims description 111
- 239000000523 sample Substances 0.000 claims description 104
- 238000000034 method Methods 0.000 claims description 84
- 102100032752 C-reactive protein Human genes 0.000 claims description 66
- 206010000891 acute myocardial infarction Diseases 0.000 claims description 64
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 60
- 238000011282 treatment Methods 0.000 claims description 59
- 239000013068 control sample Substances 0.000 claims description 54
- 230000003247 decreasing effect Effects 0.000 claims description 48
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 32
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims description 31
- YDNKGFDKKRUKPY-TURZORIXSA-N N-hexadecanoylsphingosine Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)\C=C\CCCCCCCCCCCCC YDNKGFDKKRUKPY-TURZORIXSA-N 0.000 claims description 31
- ZJVVOYPTFQEGPH-UHFFFAOYSA-N 102917-80-6 Natural products CCCCCCCCCCCCCCCCCCCCCCCC(=O)NC(CO)C(O)C=CCCCCCCCCCCCCC ZJVVOYPTFQEGPH-UHFFFAOYSA-N 0.000 claims description 30
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 30
- ZJVVOYPTFQEGPH-AUTSUKAISA-N N-tetracosanoylsphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)\C=C\CCCCCCCCCCCCC ZJVVOYPTFQEGPH-AUTSUKAISA-N 0.000 claims description 30
- 229940079593 drug Drugs 0.000 claims description 29
- 239000003814 drug Substances 0.000 claims description 29
- 238000002560 therapeutic procedure Methods 0.000 claims description 18
- 235000012000 cholesterol Nutrition 0.000 claims description 16
- 230000009469 supplementation Effects 0.000 claims description 16
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims description 12
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims description 12
- 108010010234 HDL Lipoproteins Proteins 0.000 claims description 12
- 102000015779 HDL Lipoproteins Human genes 0.000 claims description 12
- YMQZQHIESOAPQH-JXGHDCMNSA-N N-heptadecanoylsphingosine-1-phosphocholine Chemical compound CCCCCCCCCCCCCCCCC(=O)N[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)[C@H](O)\C=C\CCCCCCCCCCCCC YMQZQHIESOAPQH-JXGHDCMNSA-N 0.000 claims description 12
- IPRFVQMZNCETMH-YDIFVNDFSA-N alpha-D-Gal-(1->4)-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-Cer(d18:1/22:0) Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O1 IPRFVQMZNCETMH-YDIFVNDFSA-N 0.000 claims description 12
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 12
- 101710095342 Apolipoprotein B Proteins 0.000 claims description 11
- 102100040202 Apolipoprotein B-100 Human genes 0.000 claims description 11
- 210000002966 serum Anatomy 0.000 claims description 10
- 102000030169 Apolipoprotein C-III Human genes 0.000 claims description 8
- 108010056301 Apolipoprotein C-III Proteins 0.000 claims description 8
- 108010023302 HDL Cholesterol Proteins 0.000 claims description 8
- 108010028554 LDL Cholesterol Proteins 0.000 claims description 8
- 201000001320 Atherosclerosis Diseases 0.000 claims description 6
- QEDPUVGSSDPBMD-XTAIVQBESA-N N-lignoceroylsphingosine-1-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)[C@H](O)\C=C\CCCCCCCCCCCCC QEDPUVGSSDPBMD-XTAIVQBESA-N 0.000 claims description 6
- 230000004048 modification Effects 0.000 claims description 6
- 238000012986 modification Methods 0.000 claims description 6
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 claims description 4
- 102000018616 Apolipoproteins B Human genes 0.000 claims description 4
- 108010027006 Apolipoproteins B Proteins 0.000 claims description 4
- 102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 claims description 4
- 108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 claims description 4
- 102000004895 Lipoproteins Human genes 0.000 claims description 4
- 108090001030 Lipoproteins Proteins 0.000 claims description 4
- 108020004459 Small interfering RNA Proteins 0.000 claims description 4
- 229960003765 fluvastatin Drugs 0.000 claims description 4
- 238000004949 mass spectrometry Methods 0.000 claims description 4
- 208000010125 myocardial infarction Diseases 0.000 claims description 4
- 210000002381 plasma Anatomy 0.000 claims description 4
- 230000036470 plasma concentration Effects 0.000 claims description 4
- 239000004055 small Interfering RNA Substances 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- 210000002700 urine Anatomy 0.000 claims description 4
- 239000003524 antilipemic agent Substances 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- VTAKZNRDSPNOAU-UHFFFAOYSA-M 2-(chloromethyl)oxirane;hydron;prop-2-en-1-amine;n-prop-2-enyldecan-1-amine;trimethyl-[6-(prop-2-enylamino)hexyl]azanium;dichloride Chemical compound Cl.[Cl-].NCC=C.ClCC1CO1.CCCCCCCCCCNCC=C.C[N+](C)(C)CCCCCCNCC=C VTAKZNRDSPNOAU-UHFFFAOYSA-M 0.000 claims description 2
- 108020005544 Antisense RNA Proteins 0.000 claims description 2
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 2
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims description 2
- -1 Cer18: 1/24: 0 Chemical compound 0.000 claims description 2
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 claims description 2
- 229920001268 Cholestyramine Polymers 0.000 claims description 2
- 229920002905 Colesevelam Polymers 0.000 claims description 2
- 229920002911 Colestipol Polymers 0.000 claims description 2
- 238000002965 ELISA Methods 0.000 claims description 2
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 claims description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 2
- 238000005481 NMR spectroscopy Methods 0.000 claims description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 2
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims description 2
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 2
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- MZZLGJHLQGUVPN-HAWMADMCSA-N anacetrapib Chemical compound COC1=CC(F)=C(C(C)C)C=C1C1=CC=C(C(F)(F)F)C=C1CN1C(=O)O[C@H](C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)[C@@H]1C MZZLGJHLQGUVPN-HAWMADMCSA-N 0.000 claims description 2
- 229950000285 anacetrapib Drugs 0.000 claims description 2
- 239000012491 analyte Substances 0.000 claims description 2
- 238000003556 assay Methods 0.000 claims description 2
- 229960005370 atorvastatin Drugs 0.000 claims description 2
- 229960000516 bezafibrate Drugs 0.000 claims description 2
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 claims description 2
- 229920000080 bile acid sequestrant Polymers 0.000 claims description 2
- 229960005110 cerivastatin Drugs 0.000 claims description 2
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 229960001214 clofibrate Drugs 0.000 claims description 2
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 claims description 2
- 229960001152 colesevelam Drugs 0.000 claims description 2
- 229960002604 colestipol Drugs 0.000 claims description 2
- GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 claims description 2
- 239000003184 complementary RNA Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 208000029078 coronary artery disease Diseases 0.000 claims description 2
- 235000015872 dietary supplement Nutrition 0.000 claims description 2
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 claims description 2
- 229960000815 ezetimibe Drugs 0.000 claims description 2
- 229960002297 fenofibrate Drugs 0.000 claims description 2
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 claims description 2
- 229940125753 fibrate Drugs 0.000 claims description 2
- 238000001506 fluorescence spectroscopy Methods 0.000 claims description 2
- 229960003627 gemfibrozil Drugs 0.000 claims description 2
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 2
- 238000003018 immunoassay Methods 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 238000005305 interferometry Methods 0.000 claims description 2
- 229960004844 lovastatin Drugs 0.000 claims description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 2
- 229950009116 mevastatin Drugs 0.000 claims description 2
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 claims description 2
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 claims description 2
- 239000013642 negative control Substances 0.000 claims description 2
- 208000030613 peripheral artery disease Diseases 0.000 claims description 2
- 229960002797 pitavastatin Drugs 0.000 claims description 2
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims description 2
- 230000010287 polarization Effects 0.000 claims description 2
- 239000013641 positive control Substances 0.000 claims description 2
- 229960002965 pravastatin Drugs 0.000 claims description 2
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims description 2
- 229960000672 rosuvastatin Drugs 0.000 claims description 2
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims description 2
- IMNTVVOUWFPRSB-JWQCQUIFSA-N sch-48461 Chemical compound C1=CC(OC)=CC=C1[C@H]1N(C=2C=CC(OC)=CC=2)C(=O)[C@@H]1CCCC1=CC=CC=C1 IMNTVVOUWFPRSB-JWQCQUIFSA-N 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 229960002855 simvastatin Drugs 0.000 claims description 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 2
- 150000003384 small molecules Chemical group 0.000 claims description 2
- CMSGWTNRGKRWGS-NQIIRXRSSA-N torcetrapib Chemical compound COC(=O)N([C@H]1C[C@@H](CC)N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OCC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CMSGWTNRGKRWGS-NQIIRXRSSA-N 0.000 claims description 2
- 229950004514 torcetrapib Drugs 0.000 claims description 2
- 238000001195 ultra high performance liquid chromatography Methods 0.000 claims description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 claims description 2
- KEPQASGDXIEOIL-UHFFFAOYSA-N (2S,3R)-N-(docosanoate)-1,3-dihydroxy-2-amino-octadeca-4-(E)-ene Natural products CCCCCCCCCCCCCCCCCCCCCC(=O)NC(CO)C(O)C=CCCCCCCCCCCCCC KEPQASGDXIEOIL-UHFFFAOYSA-N 0.000 claims 3
- KEPQASGDXIEOIL-GLQCRSEXSA-N N-docosanoylsphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)\C=C\CCCCCCCCCCCCC KEPQASGDXIEOIL-GLQCRSEXSA-N 0.000 claims 3
- VODZWWMEJITOND-NXCSZAMKSA-N N-octadecanoylsphingosine Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)\C=C\CCCCCCCCCCCCC VODZWWMEJITOND-NXCSZAMKSA-N 0.000 claims 3
- 230000035945 sensitivity Effects 0.000 claims 3
- 229940122392 PCSK9 inhibitor Drugs 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- YZQLWPMZQVHJED-UHFFFAOYSA-N 2-methylpropanethioic acid S-[2-[[[1-(2-ethylbutyl)cyclohexyl]-oxomethyl]amino]phenyl] ester Chemical compound C=1C=CC=C(SC(=O)C(C)C)C=1NC(=O)C1(CC(CC)CC)CCCCC1 YZQLWPMZQVHJED-UHFFFAOYSA-N 0.000 description 1
- 229940096699 bile acid sequestrants Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161556915P | 2011-11-08 | 2011-11-08 | |
| EP11188325.2A EP2592422A1 (en) | 2011-11-08 | 2011-11-08 | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment |
| EP11188325.2 | 2011-11-08 | ||
| US61/556,915 | 2011-11-08 | ||
| PCT/EP2012/071973 WO2013068374A2 (en) | 2011-11-08 | 2012-11-07 | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014532886A JP2014532886A (ja) | 2014-12-08 |
| JP2014532886A5 true JP2014532886A5 (cg-RX-API-DMAC7.html) | 2016-03-24 |
| JP6388284B2 JP6388284B2 (ja) | 2018-09-12 |
Family
ID=45033776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014540427A Active JP6388284B2 (ja) | 2011-11-08 | 2012-11-07 | スタチン治療を受けている冠動脈疾患患者の心血管転帰を予測するためのリピドミックバイオマーカー |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US9052327B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2592422A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6388284B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN104024860B (cg-RX-API-DMAC7.html) |
| CA (1) | CA2854422A1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1202154A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013068374A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9806270B2 (en) | 2011-03-25 | 2017-10-31 | Udc Ireland Limited | 4H-imidazo[1,2-a]imidazoles for electronic applications |
| EP2592423A1 (en) | 2011-11-08 | 2013-05-15 | Zora Biosciences OY | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment |
| CN108299439B (zh) | 2011-11-10 | 2021-02-09 | Udc 爱尔兰有限责任公司 | 用于电子应用的4H-咪唑并[1,2-a]咪唑 |
| ES2552371T3 (es) * | 2012-05-25 | 2015-11-27 | Zora Biosciences Oy | Biomarcadores sensibles, eficaces e inocuos, para la inhibición de la Proproteína Convertasa Subtilisina/Kexina de tipo 9 (PCSK9) |
| JP6231561B2 (ja) | 2012-07-10 | 2017-11-15 | ユー・ディー・シー アイルランド リミテッド | 電子用途のためのベンズイミダゾ［１，２−ａ］ベンズイミダゾール誘導体 |
| NZ724790A (en) | 2014-04-10 | 2022-07-29 | MEP Equine Solutions LLC | Method for the quantification of parasite eggs in feces |
| US9347960B2 (en) | 2014-06-16 | 2016-05-24 | Zora Biosciences, Oy | Ceramides and their use in diagnosing CVD |
| WO2016100549A2 (en) * | 2014-12-16 | 2016-06-23 | Washington University | Ceramides for evaluating risk of cardiovascular disease |
| WO2017097852A2 (en) | 2015-12-07 | 2017-06-15 | Zora Biosciences Oy | Use of ceramides and lpls in diagnosing cvd |
| CN105486773A (zh) * | 2015-12-25 | 2016-04-13 | 齐炼文 | 用于诊断冠心病的代谢标志物 |
| CN105424841B (zh) * | 2015-12-25 | 2017-11-03 | 齐炼文 | 用于诊断冠状动脉粥样硬化的代谢标志物 |
| CN105628809B (zh) * | 2015-12-25 | 2018-04-03 | 中国药科大学 | 用于诊断区分冠状动脉粥样硬化和冠心病的代谢标志物 |
| KR102003309B1 (ko) * | 2016-12-05 | 2019-07-25 | 한국과학기술연구원 | 대사체 및 임상지표를 활용한 관상동맥 심장질환 진단용 키트 및 기초 정보 제공 방법 |
| CN107144648B (zh) * | 2017-04-26 | 2019-11-22 | 苏州海科医药技术有限公司 | 检测人血浆中匹伐他汀的液相色谱-串联质谱方法 |
| CN107014942A (zh) * | 2017-05-05 | 2017-08-04 | 北京骐骥生物技术有限公司 | 利用脂质生物标志物预测糖尿病冠心病的方法 |
| WO2019119049A1 (en) * | 2017-12-20 | 2019-06-27 | Baker Heart and Diabetes Institute | Method of predicting drug therapeutic responder status and methods of treatment |
| US12441815B2 (en) | 2018-11-02 | 2025-10-14 | The Regents Of The University Of California | Compositions and methods for diagnosis of cardiovascular disease |
| WO2020112149A1 (en) * | 2018-12-01 | 2020-06-04 | Binhai Industrial Technology Research Institute Of Zhejiang University | Methods and compositions for the assessment of acute myocardial infarction (ami) |
| EP3891509A1 (en) | 2018-12-06 | 2021-10-13 | Zora Biosciences OY | Biomarkers for cardiovascular events |
| CN109828076B (zh) * | 2019-04-11 | 2020-07-21 | 江南大学 | 一种高效薄层色谱联用生物发光法筛查贝特类降脂化学药掺伪的方法 |
| CN112630344B (zh) * | 2020-12-08 | 2021-12-14 | 河北医科大学第二医院 | 代谢标志物在脑梗死中的用途 |
| CN113533754A (zh) * | 2021-07-12 | 2021-10-22 | 北京市心肺血管疾病研究所 | 神经酰胺在制备用于评估高血压患者发生不良事件风险的试剂盒中的应用 |
| CN113567583B (zh) * | 2021-07-22 | 2022-06-07 | 江南大学 | 应用固相萃取-超临界流体色谱-质谱法检测乳中极性脂的方法 |
| CN116087485B (zh) * | 2021-11-08 | 2023-10-20 | 中国医学科学院阜外医院 | 糖尿病患者早期预测心血管疾病（cvd）的生物标志物及其用途 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE489633T1 (de) * | 1997-06-10 | 2010-12-15 | Lpath Inc | Verfahren zum frühzeitigen nachweis herzerkrankungen |
| WO2004038381A2 (en) | 2002-10-25 | 2004-05-06 | Metabolon, Inc. | Methods for drug discovery, disease treatment, and diagnosis using metabolomics |
| US7972802B2 (en) | 2005-10-31 | 2011-07-05 | University Of Washington | Lipoprotein-associated markers for cardiovascular disease |
| US8137977B2 (en) * | 2006-04-24 | 2012-03-20 | Children's Hospital & Research Center At Oakland | Lipidomic approaches to determining drug response phenotypes in cardiovascular disease |
| DE102006034153B4 (de) | 2006-07-24 | 2018-02-08 | Magna powertrain gmbh & co kg | Getriebe |
| EP2153236A1 (en) | 2007-06-07 | 2010-02-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for assessing the risk of a cardiovascular disease and for diagnosing dyslipidemia |
| EP2048243A1 (en) | 2007-09-24 | 2009-04-15 | sanofi-aventis | Use of clec1B for the determination of cardiovascular and thrombotic risk |
| CN101939651A (zh) * | 2007-10-10 | 2011-01-05 | 保函医药公司 | 用于检测严重有害的心血管和脑血管事件的方法 |
| US9213030B2 (en) | 2008-01-28 | 2015-12-15 | National University Of Singapore | Lipid tumour profile |
| AU2009224114B2 (en) | 2008-03-12 | 2013-02-21 | Otago Innovation Limited | Biomarkers |
| AU2009224113B2 (en) * | 2008-03-12 | 2013-02-21 | Otago Innovation Limited | Biomarkers |
| ES2640900T3 (es) | 2008-10-30 | 2017-11-07 | Firalis | Biomarcadores |
| US20110034419A1 (en) * | 2009-06-27 | 2011-02-10 | Musc Foundation For Research Development | Cardioprotective Drugs and Diagnostics for Assessing Risk of Cardiovascular Disease |
| ES2768995T3 (es) * | 2009-11-17 | 2020-06-24 | Baylor Res Institute | 1-desoxigalactonojirimicina para el uso en el tratamiento de una enfermedad cardíaca |
| WO2011063470A1 (en) | 2009-11-27 | 2011-06-03 | Baker Idi Heart And Diabetes Institute Holdings Limited | Lipid biomarkers for stable and unstable heart disease |
| NO2385374T3 (cg-RX-API-DMAC7.html) * | 2010-05-05 | 2014-06-07 | ||
| EP2583107A2 (en) * | 2010-06-20 | 2013-04-24 | Zora Biosciences OY | Lipidomic biomarkers for identification of high-risk coronary artery disease patients |
| EP2400573A1 (de) | 2010-06-23 | 2011-12-28 | Bayer MaterialScience AG | Elektromechanischer Wandler, Verfahren zu dessen Herstellung und Verwendung desselben |
| US9664698B2 (en) | 2011-04-08 | 2017-05-30 | Zora Biosciences Oy | Biomarkers for sensitive detection of statin-induced muscle toxicity |
| FI20115576A0 (fi) * | 2011-06-10 | 2011-06-10 | Teknologian Tutkimuskeskus Vtt Oy | Menetelmä Alzheimerin taudin diagnoimiseksi |
| EP2592423A1 (en) | 2011-11-08 | 2013-05-15 | Zora Biosciences OY | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment |
-
2011
- 2011-11-08 EP EP11188325.2A patent/EP2592422A1/en not_active Withdrawn
-
2012
- 2012-11-07 CN CN201280054322.3A patent/CN104024860B/zh active Active
- 2012-11-07 CA CA2854422A patent/CA2854422A1/en not_active Abandoned
- 2012-11-07 US US14/356,474 patent/US9052327B2/en active Active
- 2012-11-07 JP JP2014540427A patent/JP6388284B2/ja active Active
- 2012-11-07 WO PCT/EP2012/071973 patent/WO2013068374A2/en not_active Ceased
- 2012-11-07 HK HK15102546.8A patent/HK1202154A1/xx unknown
- 2012-11-07 EP EP12784242.5A patent/EP2776842B1/en active Active
-
2015
- 2015-05-28 US US14/723,754 patent/US9459265B2/en active Active
-
2016
- 2016-08-29 US US15/249,935 patent/US20160363602A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014532886A5 (cg-RX-API-DMAC7.html) | ||
| JP2014532885A5 (cg-RX-API-DMAC7.html) | ||
| JP2013531238A5 (cg-RX-API-DMAC7.html) | ||
| Jacobson | Opening a new lipid “apo-thecary”: incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk | |
| Patel et al. | A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis | |
| Ni et al. | Antiinflammatory and antiarteriosclerotic actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis | |
| Sager et al. | Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein | |
| Sager et al. | Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients | |
| Ky et al. | The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans | |
| Masuda et al. | Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia | |
| Valkonen et al. | Asymmetrical dimethylarginine (ADMA) and risk of acute coronary events: Does statin treatment influence plasma ADMA levels? | |
| Hothersall et al. | Effects of atorvastatin added to inhaled corticosteroids on lung function and sputum cell counts in atopic asthma | |
| Jick et al. | Hyperlipidaemia, statin use and the risk of developing rheumatoid arthritis | |
| Guo et al. | Short-term impact of low-dose atorvastatin on serum proprotein convertase subtilisin/kexin type 9 | |
| Kanbay et al. | Statin therapy helps to control blood pressure levels in hypertensive dyslipidemic patients | |
| McKenney et al. | Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia | |
| Rudofsky et al. | Identical LDL-cholesterol lowering but non-identical effects on NF-κB activity: High dose simvastatin vs combination therapy with ezetimibe | |
| Mori et al. | Fasting serum concentration of apolipoprotein B48 represents residual risks in patients with new-onset and chronic coronary artery disease | |
| Astengo et al. | Physical training after percutaneous coronary intervention in patients with stable angina: effects on working capacity, metabolism, and markers of inflammation | |
| JP2015526696A5 (cg-RX-API-DMAC7.html) | ||
| Yeang et al. | Lipoprotein (a)-cholesterol levels estimated by vertical auto profile correlate poorly with Lp (a) mass in hyperlipidemic subjects: implications for clinical practice interpretation of Lp (a)-mediated risk | |
| Tani et al. | Association of atherosclerosis-related markers and its relationship to n-3 polyunsaturated fatty acids levels with a prevalence of coronary artery disease in an urban area in Japan | |
| Agouridis et al. | The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia | |
| Tian et al. | Efficacy comparison of atorvastatin versus rosuvastatin on blood lipid and microinflammatory state in maintenance hemodialysis patients | |
| Thongtang et al. | Effects of atorvastatin on human C-reactive protein metabolism |